Published in Eur Heart J on April 17, 2013
The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol (2014) 2.13
Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness. Hypertension (2013) 1.59
Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes (2014) 0.91
Mineralocorticoid receptor antagonism treats obesity-associated cardiac diastolic dysfunction. Hypertension (2015) 0.90
Regional variation in arterial stiffening and dysfunction in Western diet-induced obesity. Am J Physiol Heart Circ Physiol (2015) 0.89
Endothelial Mineralocorticoid Receptor Deletion Prevents Diet-Induced Cardiac Diastolic Dysfunction in Females. Hypertension (2015) 0.88
Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure. Hypertension (2015) 0.88
Mineralocorticoid receptor blockade prevents Western diet-induced diastolic dysfunction in female mice. Am J Physiol Heart Circ Physiol (2015) 0.88
Mineralocorticoid Receptors in the Pathophysiology of Vascular Inflammation and Atherosclerosis. Front Endocrinol (Lausanne) (2015) 0.84
Mineralocorticoid receptor throughout the vessel: a key to vascular dysfunction in obesity. Eur Heart J (2013) 0.84
Androgens influence microvascular dilation in PCOS through ET-A and ET-B receptors. Am J Physiol Endocrinol Metab (2013) 0.83
Aldosterone's rapid, nongenomic effects are mediated by striatin: a modulator of aldosterone's effect on estrogen action. Endocrinology (2014) 0.82
Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice. PLoS One (2014) 0.81
Endothelial cell mineralocorticoid receptors: turning cardiovascular risk factors into cardiovascular dysfunction. Hypertension (2014) 0.80
Mineralocorticoid receptors: an appealing target to treat coronary microvascular dysfunction in diabetes. Diabetes (2015) 0.80
Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney Int (2016) 0.80
The Role of Aldosterone in Obesity-Related Hypertension. Am J Hypertens (2016) 0.77
Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults. Exp Gerontol (2015) 0.76
The endothelial mineralocorticoid receptor: mediator of the switch from vascular health to disease. Curr Opin Nephrol Hypertens (2016) 0.75
Aldosterone in vascular and metabolic dysfunction. Curr Opin Nephrol Hypertens (2016) 0.75
Effect of mineralocorticoid receptor blockade on hippocampal-dependent memory in adults with obesity. Obesity (Silver Spring) (2015) 0.75
Mild endothelial dysfunction in Sirt3 knockout mice fed a high-cholesterol diet: protective role of a novel C/EBP-β-dependent feedback regulation of SOD2. Basic Res Cardiol (2016) 0.75
Uncovering a Mineralocorticoid Receptor-Dependent Adipose-Vascular Axis: Implications for Vascular Dysfunction in Obesity? Diabetes (2016) 0.75
Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1. J Am Soc Nephrol (2017) 0.75
Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. Basic Res Cardiol (2017) 0.75
Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis. Front Pharmacol (2017) 0.75
30 YEARS OF THE MINERALOCORTICOID RECEPTOR: The role of the mineralocorticoid receptor in the vasculature. J Endocrinol (2017) 0.75
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 29.32
Inflammation, stress, and diabetes. J Clin Invest (2005) 17.11
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med (2003) 13.25
MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest (2006) 12.32
Obesity and the regulation of energy balance. Cell (2001) 9.48
Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation (2002) 3.95
VE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells. Dev Dyn (2006) 3.38
GPR30 expression is required for the mineralocorticoid receptor-independent rapid vascular effects of aldosterone. Hypertension (2011) 3.26
Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol (2002) 2.94
The obesity epidemic, metabolic syndrome and future prevention strategies. Eur J Cardiovasc Prev Rehabil (2004) 2.79
Adipose tissue as an endocrine organ. Obesity (Silver Spring) (2006) 2.63
The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med (1989) 2.51
Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension (1986) 2.30
Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med (2007) 2.23
Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats. Hypertension (2005) 1.83
Obesity increases prostanoid-mediated vasoconstriction and vascular thromboxane receptor gene expression. J Hypertens (2002) 1.77
Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res (2008) 1.76
Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A (2003) 1.74
Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation (2008) 1.73
Aorta of ApoE-deficient mice responds to atherogenic stimuli by a prelesional increase and subsequent decrease in the expression of antioxidant enzymes. Circ Res (2003) 1.72
Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J (2007) 1.72
Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension (2007) 1.68
Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation (2004) 1.67
Development of a panel of monoclonal antibodies against the mineralocorticoid receptor. Endocrinology (2005) 1.61
Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res (2009) 1.41
Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women. Obes Res (1999) 1.34
The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J (2010) 1.24
Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide bioavailability. FASEB J (2001) 1.21
Endothelium-dependent contractions occur in the aorta of wild-type and COX2-/- knockout but not COX1-/- knockout mice. J Cardiovasc Pharmacol (2005) 1.19
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension (2002) 1.18
Aldosterone induces superoxide generation via Rac1 activation in endothelial cells. Endocrinology (2007) 1.18
Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension (2004) 1.17
Mechanisms of endothelial dysfunction in obesity. Clin Chim Acta (2005) 1.15
Aldosterone in obesity. Endocr Res (1999) 1.12
Vasoconstrictor prostanoids. Pflugers Arch (2010) 1.09
Macrophage mineralocorticoid receptor signaling plays a key role in aldosterone-independent cardiac fibrosis. Endocrinology (2012) 1.05
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure. Am Heart J (2010) 1.03
Aldosterone induces endothelial dysfunction in resistance arteries from normotensive and hypertensive rats by increasing thromboxane A2 and prostacyclin. Br J Pharmacol (2008) 1.03
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol (2006) 0.98
Effect of single treatment with the antihypertensive drug eplerenone on hormone levels and anxiety-like behaviour in rats. Endocr Regul (2008) 0.77
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J (2013) 9.54
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med (2015) 6.00
Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med (2009) 5.34
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation (2003) 4.61
Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science (2006) 4.21
Statins and the risk of cancer after heart transplantation. Circulation (2012) 4.06
Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content: role of habitual versus nonhabitual drinking. Circulation (2002) 3.83
Inhibition of the renin-angiotensin system does not reduce platelet activity at rest or during stress in hypertension. J Hypertens (2013) 3.20
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet (2007) 3.20
Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2. Immunity (2013) 2.74
Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci U S A (2005) 2.73
Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene. Circ Res (2006) 2.71
The assessment of endothelial function: from research into clinical practice. Circulation (2012) 2.68
Natural Course of Paravalvular Regurgitation After Implantation of the Self-Expanding CoreValve: Insights From Serial TEE Measurements. J Invasive Cardiol (2015) 2.62
Effect of high-dosage cholecalciferol and extended physiotherapy on complications after hip fracture: a randomized controlled trial. Arch Intern Med (2010) 2.59
Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: a monitoring test of endothelial dysfunction for clinical practice? J Am Coll Cardiol (2003) 2.59
High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS (2010) 2.49
Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation (2002) 2.45
High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation (2003) 2.44
Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock: results of the Impella-EUROSHOCK-registry. Circ Heart Fail (2012) 2.41
Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science (2004) 2.38
Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest (2011) 2.37
Cocoa and cardiovascular health. Circulation (2009) 2.29
Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens (2004) 2.26
Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications. Circulation (2006) 2.12
Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling. Circulation (2013) 2.11
Dynamic expression profile of p21WAF1/CIP1 and Ki-67 predicts survival in rectal carcinoma treated with preoperative radiochemotherapy. J Clin Oncol (2003) 2.04
Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation (2003) 2.00
Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation (2002) 1.94
ERK signaling is a central regulator for BMP-4 dependent capillary sprouting. Cardiovasc Res (2007) 1.90
Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE-/- mice. Hypertension (2004) 1.89
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Selective inhibition of protein kinase Cbeta2 prevents acute effects of high glucose on vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation (2004) 1.88
Acetaminophen increases blood pressure in patients with coronary artery disease. Circulation (2010) 1.85
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation (2008) 1.85
Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation (2007) 1.83
Transcatheter aortic valve implantation (TAVI) outcome according to standardized endpoint definitions by the Valve Academic Research Consortium (VARC). J Invasive Cardiol (2011) 1.82
Engineered disulfide bonds support the functional rotation mechanism of multidrug efflux pump AcrB. Nat Struct Mol Biol (2008) 1.81
From abstract to impact in cardiovascular research: factors predicting publication and citation. Eur Heart J (2012) 1.79
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest (2010) 1.78
Cardiovascular disease in HIV infection. Am Heart J (2006) 1.78
Septicemia caused by tick-borne bacterial pathogen Candidatus Neoehrlichia mikurensis. Emerg Infect Dis (2010) 1.75
Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop. Proc Natl Acad Sci U S A (2012) 1.66
Torcetrapib impairs endothelial function in hypertension. Eur Heart J (2011) 1.66
Activation of system L heterodimeric amino acid exchangers by intracellular substrates. EMBO J (2002) 1.66
Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation (2013) 1.64
Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation (2002) 1.64
High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation (2002) 1.63
Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. Proc Natl Acad Sci U S A (2007) 1.63
Electrophysiological findings in patients with isolated left ventricular non-compaction. Europace (2009) 1.61
Depletion of FOXP3+ regulatory T cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest (2013) 1.61
Dysfunctional baroreflex regulation of sympathetic nerve activity in patients with vasovagal syncope. Circulation (2003) 1.60
Aqp2-expressing cells give rise to renal intercalated cells. J Am Soc Nephrol (2013) 1.59
Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension (2011) 1.59
Systemic inhibition of nitric oxide synthase unmasks neural constraint of maximal myocardial blood flow in humans. Circulation (2004) 1.59
Cardiovascular effects of flavanol-rich chocolate in patients with heart failure. Eur Heart J (2011) 1.59
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clin Sci (Lond) (2011) 1.59
Metaplasticity of amygdalar responses to the stress hormone corticosterone. Proc Natl Acad Sci U S A (2010) 1.58
SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med (2004) 1.55
Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension (2005) 1.54
Impact of vessel size on outcome after implantation of sirolimus-eluting and paclitaxel-eluting stents: a subgroup analysis of the SIRTAX trial. J Am Coll Cardiol (2007) 1.54
TLR-4 deficiency protects against focal cerebral ischemia and axotomy-induced neurodegeneration. Neurobiol Dis (2008) 1.52
Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. Eur Heart J (2010) 1.51
Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol (2007) 1.51
Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients. J Hypertens (2012) 1.50
Oxidative stress in patients with end-stage renal disease prior to the start of renal replacement therapy. Nephron Clin Pract (2004) 1.48
Protective roles of SIRT1 in atherosclerosis. Cell Cycle (2011) 1.47
Nitric-oxide-mediated relaxations in salt-induced hypertension: effect of chronic beta1 -selective receptor blockade. J Hypertens (2002) 1.47